Since CCL21 is produced by lymphatic endothelium, and known to drive lymphatic-directed immune cell traffic [13,14], it has been hypothesized that tumor cells may usurp this pathway in order to drive lymphatic invasion by over-expressing the CCR7 receptor [8,9,15]. The gene discussed is CCL21; the disease is neoplasm.